Please find attached un-audited financial results of the Company for the quarter ended on June 30, 2026
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 30 Jul 2026, 03:28 PM IST · BSE ID: fa18ad62-069e-40bf-87c3-061d22c86a1f
View Original BSE Filing (PDF)
💡
In Simple Terms
Mankind Pharma released its latest quarterly financial results, showing its profit and sales for the April-June 2026 period.
🤖 AI Summary
- Mankind Pharma reported unaudited standalone net profit of Rs. 558.49 crore for the quarter ended June 30, 2026.
- Revenue from operations stood at Rs. 2,964.05 crore for the first quarter of FY27.
- The Board approved the issuance of a corporate guarantee in favor of Bharat Serums and Vaccines Limited.
- Comparative standalone financial results for Q1 FY26 were restated due to a business combination during FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27)
Rs. 2,964.05 crore
15.34%
Total income (Q1 FY27)
Rs. 2,998.01 crore
13.79%
Profit for the period (Q1 FY27)
Rs. 558.49 crore
34.49%
Basic EPS (Q1 FY27)
Rs. 13.53
34.49%
Finance costs (Q1 FY27)
Rs. 94.95 crore
-36.30%
🏢 How This Affects the Company
The company's core pharmaceutical and healthcare operations generated Rs. 2,964.05 crore in revenue, marking its financial performance for the quarter.
The financial results confirm a net profit of Rs. 558.49 crore for the quarter. The issuance of a corporate guarantee to a wholly-owned subsidiary could affect contingent liabilities.
The emphasis of matter note highlights an ongoing uncertainty regarding income tax proceedings initiated against the company, with an appeal pending.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the increase in basic EPS to Rs. 13.53 from Rs. 10.06 year-on-year.
🔍
Management Signal
The Board's approval of financial results and a corporate guarantee issuance indicates ongoing operational and financial management activities, alongside compliance with regulatory requirements.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor revenue and profit trends.
Updates on the pending income tax proceedings with appellate authorities.
Further details on the corporate guarantee issued for Bharat Serums and Vaccines Limited.
MEDIUM RISK
Ongoing income tax proceedings create financial uncertainty; audit reports note non-joint reviews for certain partnership firms.
💡 Investor Takeaway
Mankind Pharma's unaudited standalone financial results for Q1 FY27 show profit of Rs. 558.49 crore, up from Rs. 415.27 crore year-on-year. Revenue from operations increased to Rs. 2,964.05 crore from Rs. 2,569.73 crore in the comparable prior period.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from operations increased to Rs. 2,964.05 crore for the quarter ended June 30, 2026, up from Rs. 2,569.73 crore in Q1 FY26.
- Profit for the period rose to Rs. 558.49 crore in Q1 FY27, compared to Rs. 415.27 crore in the same period last year.
⚠️ Concerns
- Ongoing uncertainty regarding income tax proceedings initiated against the company by the Income Tax Department, with an appeal pending.
- Finance costs remained substantial at Rs. 94.95 crore for the quarter ended June 30, 2026, though lower than Rs. 149.34 crore in Q1 FY26.
📅 Company Track Record
No previous filings found for Mankind Pharma Ltd. on the ForgeUp platform. This filing represents the first public financial disclosure captured for the company in this context.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Mankind Pharma's standalone net profit for the quarter ended June 30, 2026?
Mankind Pharma reported an unaudited standalone net profit of Rs. 558.49 crore for the quarter ended June 30, 2026.
What was Mankind Pharma's revenue from operations for Q1 FY27?
Revenue from operations for Mankind Pharma stood at Rs. 2,964.05 crore for the quarter ended June 30, 2026.
What was Mankind Pharma's basic earnings per share (EPS) for the quarter ended June 30, 2026?
The basic EPS for Mankind Pharma for the quarter ended June 30, 2026, was Rs. 13.53.
What significant corporate action did Mankind Pharma's Board approve on July 30, 2026?
The Board of Directors approved the issuance of a corporate guarantee in favor of Bharat Serums and Vaccines Limited, a wholly-owned subsidiary.
Are Mankind Pharma's financial results for June 30, 2025, comparable?
The comparative unaudited standalone financial results for the quarter ended June 30, 2025, have been restated due to adjustments from a business combination accounted for during the year ended March 31, 2026.
Questions based on this BSE filing only. For information purposes.